Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 27;21 Suppl 1(Suppl 1):S32-40.
doi: 10.2119/molmed.2015.00067.

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Affiliations
Free PMC article

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Sho-Ichi Yamagishi et al. Mol Med. .
Free PMC article

Abstract

A nonenzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules and subsequently alters their structural integrity and function. This process has been known to progress at an accelerated rate under hyperglycemic and/or oxidative stress conditions. Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent and senescent macroprotein derivatives termed advanced glycation end products (AGEs). There is a growing body of evidence indicating that interaction of AGEs with their receptor (RAGE) elicits oxidative stress generation and as a result evokes proliferative, inflammatory, thrombotic and fibrotic reactions in a variety of cells. This evidence supports AGEs' involvement in diabetes- and aging-associated disorders such as diabetic vascular complications, cancer, Alzheimer's disease and osteoporosis. Therefore, inhibition of AGE formation could be a novel molecular target for organ protection in diabetes. This report summarizes the pathophysiological role of AGEs in vascular complications in diabetes and discusses the potential clinical utility of measurement of serum levels of AGEs for evaluating organ damage in diabetes.

Figures

Figure 1
Figure 1
Pathophysiological role of AGEs in diabetic vascular complications.

Similar articles

See all similar articles

Cited by 33 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback